Hospital Universitario Virgen del Rocío -ko ikertzaileekin lankidetzan egindako argitalpenak (27)

2024

  1. Spanish Consensus on Remission in Asthma (REMAS)

    Archivos de Bronconeumologia

2023

  1. COVID-19’s impact on care practice for alpha-1-antitrypsin deficiency patients

    BMC Health Services Research, Vol. 23, Núm. 1

  2. Characteristics of individuals with alpha-1 antitrypsin deficiency from Northern and Southern European countries: EARCO international registry

    The European respiratory journal

  3. Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry (Respiratory Research, (2022), 23, 1, (352), 10.1186/s12931-022-02275-4)

    Respiratory Research

  4. Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin

    International Journal of COPD, Vol. 18, pp. 1691-1700

  5. Treatment Patterns of Monoclonal Antibodies in Patients With Severe Uncontrolled Asthma Treated by Pulmonologists in Spain

    Open Respiratory Archives, Vol. 5, Núm. 3

  6. What's New in the 2022 Consensus for Severe Asthma in Adults

    Archivos de Bronconeumologia

2022

  1. Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry

    Respiratory Research, Vol. 23, Núm. 1

  2. Consensus document for severe asthma in adults. 2022 update

    Open Respiratory Archives, Vol. 4, Núm. 3

  3. Demographic and clinical characteristics of patients with α1-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO

    ERJ Open Research, Vol. 8, Núm. 3

  4. High Adherence, Microbiological Control and Reduced Exacerbations in Patients With Non-Cystic Fibrosis Bronchiectasis Treated With Nebulised Colistin. A Prospective Observational Study

    Archivos de Bronconeumologia, Vol. 58, Núm. 12, pp. 834-836

  5. Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map

    Journal of Asthma, Vol. 59, Núm. 10, pp. 1997-2007

2020

  1. Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey

    Respiratory Medicine, Vol. 170

  2. Thermoplasty in the Spotlight

    Archivos de Bronconeumologia, Vol. 56, Núm. 5, pp. 269-270

2019

  1. Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study

    PharmacoEconomics - Open, Vol. 3, Núm. 3, pp. 333-342

2018

  1. Alpha-1 antitrypsin deficiency: Outstanding questions and future directions

    Orphanet Journal of Rare Diseases, Vol. 13, Núm. 1

2017

  1. Seasonal variability in clinical care of COPD outpatients: Results from the andalusian COPD audit

    International Journal of COPD, Vol. 12, pp. 785-792

2016

  1. Determinants for changing the treatment of COPD: A regression analysis from a clinical audit

    International Journal of COPD, Vol. 11, Núm. 1, pp. 1171-1178

  2. Factors associated with fatality during the intensive phase of anti-tuberculosis treatment

    PLoS ONE, Vol. 11, Núm. 8

  3. Guideline adherence in outpatient clinics for chronic obstructive pulmonary disease: Results from a clinical audit

    PLoS ONE, Vol. 11, Núm. 3